Home>Topics>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. Headlines
  1. Ariad increases debt offering


    Thu, 12 Jun 2014

    Aria Pharmaceuticals ( ARIA -6% ) increases its debt offering to qualified institutional investors to $200M aggregate principal amount. The 3.625% convertible senior notes due 2019 will be sold via private placement. Underwriters over

  2. Aria to offer new debt


    Wed, 11 Jun 2014

    ARIAD Pharmaceuticals ( ARIA +1.9% ) plans to offer $175M aggregate principal amount convertible senior notes due 2019 in a private placement to qualified

  3. ARIAD Pharmaceuticals ( ARIA ) Presents at Jefferies 2014 Global Healthcare Conference (Transcript)


    Wed, 4 Jun 2014

    ARIAD Pharmaceuticals , Inc. ( ARIA ) Jefferies 2014 Global Healthcare ..... next presenting company is ARIAD Pharmaceuticals . ARIAD is a cancer -- largely ..... is the one representing from ARIAD Pharmaceuticals . And Tim is the President

  4. Ariad's Management Hosts the ARIAD Investor and Analyst Briefing from ASCO Conference (Transcript)


    Mon, 2 Jun 2014

    Ariad Pharmaceuticals Inc. ( ARIA ) ARIAD Investor and Analyst Briefing from ASCO Conference Transcript June 2, 2014 8:30 AM ET Executives Dr. Lyud Bazhenova

  5. Aria cancer drug shows encouraging results in clinical trial


    Mon, 2 Jun 2014

    In a 34-patient Phase 2 trial , Ariad Pharmaceuticals ' ( ARIA ) Iclusig (ponatinib) shows a clinical benefit in 50% of patients with refractory metastatic and/or unresectable gastrointestinal

  6. Ariad adopts rights plan to protect tax assets


    Fri, 1 Nov 2013

    Nov 1 (Reuters) - Ariad Pharmaceuticals Inc adopted a shareholder rights plan to protect its tax credits, a day after sales of its flagship drug Iclusig were suspended due to safety concerns...

« Prev12Next »
Content Partners